GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » ROE %
中文

Avrobio (Avrobio) ROE % : -35.57% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Avrobio ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Avrobio's annualized net income for the quarter that ended in Dec. 2023 was $-35.14 Mil. Avrobio's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $98.80 Mil. Therefore, Avrobio's annualized ROE % for the quarter that ended in Dec. 2023 was -35.57%.

The historical rank and industry rank for Avrobio's ROE % or its related term are showing as below:

AVRO' s ROE % Range Over the Past 10 Years
Min: -93.61   Med: -55.3   Max: 14.29
Current: 13.57

During the past 8 years, Avrobio's highest ROE % was 14.29%. The lowest was -93.61%. And the median was -55.30%.

AVRO's ROE % is ranked better than
92.21% of 1361 companies
in the Biotechnology industry
Industry Median: -44.08 vs AVRO: 13.57

Avrobio ROE % Historical Data

The historical data trend for Avrobio's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avrobio ROE % Chart

Avrobio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -47.35 -54.37 -56.22 -86.50 14.29

Avrobio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.46 -155.53 308.40 -76.75 -35.57

Competitive Comparison of Avrobio's ROE %

For the Biotechnology subindustry, Avrobio's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avrobio's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avrobio's ROE % distribution charts can be found below:

* The bar in red indicates where Avrobio's ROE % falls into.



Avrobio ROE % Calculation

Avrobio's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=12.157/( (75.37+94.739)/ 2 )
=12.157/85.0545
=14.29 %

Avrobio's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-35.14/( (102.858+94.739)/ 2 )
=-35.14/98.7985
=-35.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Avrobio  (NAS:AVRO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-35.14/98.7985
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-35.14 / 0)*(0 / 105.8075)*(105.8075 / 98.7985)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0709
=ROA %*Equity Multiplier
=N/A %*1.0709
=-35.57 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-35.14/98.7985
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-35.14 / -33.632) * (-33.632 / -38.508) * (-38.508 / 0) * (0 / 105.8075) * (105.8075 / 98.7985)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0448 * 0.8734 * N/A % * 0 * 1.0709
=-35.57 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Avrobio ROE % Related Terms

Thank you for viewing the detailed overview of Avrobio's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avrobio (Avrobio) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Executives
Azadeh Golipour officer: Chief Technology Officer ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason officer: Chief Scientific Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar officer: Chief Medical Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen officer: Chief Business Officer 45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay director, officer: See Remarks C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige director C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451

Avrobio (Avrobio) Headlines

From GuruFocus

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Business Wire Business Wire 08-04-2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Business Wire Business Wire 05-06-2022

AVROBIO to Explore Strategic Alternatives

By Business Wire 07-12-2023